Ernexa Therapeutics 8/13/2024 Earnings Report

Ernexa Therapeutics EPS Results

• Actual EPS: -$15.30
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Ernexa Therapeutics Revenue Results

• Actual Revenue: $0.05 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Ernexa Therapeutics Announcement Details

• Date: 8/13/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Ernexa Therapeutics (NASDAQ:ERNA), Inc. (NASDAQ: ERNA) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapies for patients suffering from central nervous system (CNS) and immune-mediated disorders. Utilizing a proprietary platform that combines medicinal chemistry with advanced biomarker screening, the company seeks to address unmet medical needs across a range of therapeutic areas, including neurodegenerative diseases, neuropathic pain and autoimmune conditions.

The company’s lead product candidate, ERN-101, is a small-molecule modulator targeting neuroinflammation pathways implicated in Alzheimer’s disease and multiple sclerosis. In parallel, Ernexa is advancing ERN-201, a monoclonal antibody designed to regulate cytokine activity in rheumatoid arthritis and other systemic autoimmune disorders. Both programs have demonstrated favorable safety and pharmacokinetic profiles in early-stage clinical trials, and the company is preparing to initiate Phase 2 studies to assess efficacy and optimal dosing strategies.

Founded in 2015 and headquartered in Boston with research facilities in Cambridge, Massachusetts, Ernexa Therapeutics has grown through a combination of in-house innovation and strategic partnerships. The company maintains collaborative agreements with leading academic institutions and contract research organizations across North America and Europe to accelerate its translational research efforts. This global footprint allows Ernexa to access diverse patient populations and leverage specialized expertise in CNS pharmacology and immunology.

Ernexa is led by a seasoned management team with deep experience in biopharmaceutical development and regulatory affairs. Chief Executive Officer Dr. Jane Mitchell co-founded the company after a 15-year tenure directing neurology research at a major pharmaceutical firm. Chief Scientific Officer Dr. Luis Alvarez brings extensive immunology credentials, having previously overseen multiple antibody programs through regulatory approval. Together with an advisory board comprising top clinicians and patient advocates, Ernexa Therapeutics is committed to advancing its pipeline toward milestones that may deliver meaningful improvements in quality of life for patients worldwide.